...We Welcome You to the Zenith Epigenetics Hub In The AGORACOM COMMUNITY!

Zenith's Lead BET Inhibitor ZEN-3694 is Currently Being Evaluated in a Phase 2 Prostate Cancer Clinical Trial

Free
AGORACOM NEWS FLASH

BREAKING: Enthusiast Gaming Targets Mobile Gaming Market with LOI to Acquire Steel Media, the Leading Global Mobile Gaming Media and Events Company

  • Will position Enthusiast as a leading publisher in the mobile gaming industry with significant growth of online and offline gaming community
  • Owner of over 20 mobile gaming websites and Pocket Gamer brand, the leading mobile gaming media website
  • Operates 25 live events in 11 countries, including the largest B2B mobile gaming event in North America and Europe

Hub On AGORACOM / Read Release

Message: Zenith share issue

"This is to finance the next leg of the Phase I trial. This would be the breast cancer leg of the trial."

Good to hear this Tada. We don't want Gilead to get too far ahead with their GS-5829 BET inhibitor breast cancer trial

On a side note the Zenith website also listed immuno-oncology as a program of interest. An Endpoints News article yesterday highlighted how crowded this field is for immuno-oncology/checkpoint therapies, which presents a big challenge for finding cancer patients for these studies. 

It will be interesting to hear Zenith at the AGM discuss their plans going forward with immuno-oncology. And if they don't talk about it, someone should ask the question if they attend the AGM!

BDAZ

Share
New Message
Please login to post a reply